Product Name :
Clozapine N-oxide dihydrochloride
Description:
Clozapine N-oxide dihydrochloride is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide dihydrochloride activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide dihydrochloride can cross the blood-brain barrier. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist.
CAS:
2250025-93-3
Molecular Weight:
415.74
Formula:
C18H21Cl3N4O
Chemical Name:
4-(8-chloro-5H-dibenzo[b, e][1, 4]diazepin-11-yl)-1-methylpiperazine 1-oxide dihydrochloride
Smiles :
Cl.Cl.C[N+]1([O-])CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C21
InChiKey:
MBRGKRXDVKTUPT-UHFFFAOYSA-N
InChi :
InChI=1S/C18H19ClN4O.2ClH/c1-23(24)10-8-22(9-11-23)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18;;/h2-7,12,20H,8-11H2,1H3;2*1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Clozapine N-oxide dihydrochloride is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide dihydrochloride activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide dihydrochloride can cross the blood-brain barrier. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist.|Product information|CAS Number: 2250025-93-3|Molecular Weight: 415.74|Formula: C18H21Cl3N4O|Chemical Name: 4-(8-chloro-5H-dibenzo[b, e][1, 4]diazepin-11-yl)-1-methylpiperazine 1-oxide dihydrochloride|Smiles: Cl.Cl.C[N+]1([O-])CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C21|InChiKey: MBRGKRXDVKTUPT-UHFFFAOYSA-N|InChi: InChI=1S/C18H19ClN4O.2ClH/c1-23(24)10-8-22(9-11-23)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18;;/h2-7,12,20H,8-11H2,1H3;2*1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 240 mg/mL (577.{{Fuzapladib} web|{Fuzapladib} Phospholipase|{Fuzapladib} Biological Activity|{Fuzapladib} References|{Fuzapladib} manufacturer|{Fuzapladib} Epigenetics} 28 mM; Need ultrasonic).{{Eblasakimab} medchemexpress|{Eblasakimab} Immunology/Inflammation|{Eblasakimab} Protocol|{Eblasakimab} References|{Eblasakimab} supplier|{Eblasakimab} Autophagy} H2O : 100 mg/mL (240.PMID:23626759 53 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Clozapine N-oxide (CNO) can bind to non-DREADD receptors at concentrations required for DREADD activation, and undergoes reverse-metabolism to its parent compound clozapine, an atypical antipsychotic that acts at a variety of pharmacological targets and produces numerous physiological and behavioral effects.|In Vivo:|After a single intraperitoneal (i.p.) injection of Clozapine N-oxide (1 mg/kg) into mice, Clozapine N-oxide (CNO) plasma levels peak at 15 min and are very low after 2 h. Despite the short plasma half-life of CNO in mice, the biological effects that have been described after acute treatment of DREADD-expressing experimental animals are usually much longer (6-10 h).|Products are for research use only. Not for human use.|
